Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 1.00 |
| ▸ | RXRB | P28702 | 2/20 | 1.00 |
| ▸ | RXRG | P48443 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.76 |
| ▸ | MAOB | P27338 | 4/20 | 0.76 |
| ▸ | MAOA | P21397 | 2/20 | 0.76 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.74 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.69 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.69 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.63 |
| ▸ | PTPRC | P08575 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784197 | 1.00 | RXRA (1.00) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL13802461 | 0.87 | NR4A2 (1.00) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL29784229 | 0.87 | NR4A2 (1.00) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL26104457 | 0.85 | RXRA (0.74) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL694229 | 0.85 | RXRA (1.00) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL22480973 | 0.85 | MRGPRX4 (1.00) | RXRARXRBRXRGNR4A2MRGPRX4 | |
| SCHEMBL1123461 | 0.83 | NR4A2 (0.81) | RXRARXRBRXRGNR4A2MRGPRX4 | |
| SCHEMBL3624161 | 0.82 | MAOB (0.73) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL6830467 | 0.82 | NR4A2 (1.00) | RXRARXRBRXRGNR4A2MAOB | |
| SCHEMBL228477 | 0.82 | NR4A2 (1.00) | RXRARXRBRXRGNR4A2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-8680150-B2 | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-04-25 | — | — | US | disclosed |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885RXRB 1966/4885RXRG 1496/4885 |
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | RXRA 4515/4885RXRB 4498/4885RXRG 4575/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | RXRA 4515/4885RXRB 4498/4885RXRG 4575/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | RXRA 3288/4885RXRB 3134/4885RXRG 3235/4885 |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | MPL, CSF3R, CSF1R | RXRA 650/4885RXRB 743/4885RXRG 504/4885 |
| US-20130102585-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | RXRA 1589/4885RXRB 1966/4885RXRG 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.